Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Metabolism and nutrition disorders – page 28

  • 741 clinical trials
  • 263 recruiting
  • 237 conditions
  • 26 countries

Conditions in this area

237 conditions with trials, the busiest first

Obesity116Type 2 diabetes mellitus83Overweight51Type 1 diabetes mellitus38Endocrine ophthalmopathy26Metabolic dysfunction-associated steatohepatitis22Diabetes mellitus21Non-alcoholic steatohepatitis17Type IIa hyperlipidaemia15Glycogen storage disease type II14Hypercholesterolaemia14Diabetic foot13Diabetic retinal oedema13Diabetic neuropathy12Alpha-1 antitrypsin deficiency11Chronic kidney disease10Fabry's disease10Osteoporosis10Hypertriglyceridaemia9Hypoparathyroidism9Acromegaly8Dyslipidaemia8Iron deficiency8Phenylketonuria8+213

Clinical trials in Metabolism and nutrition disorders

741 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

741 clinical trials

Endocrine ophthalmopathy

Not yet recruiting

Study Using Gallium-68 FAPI PET/MRI Imaging to Measure Disease Activity in Patients with Graves' Eye Disease

InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:(S)-2,2',2''-(10-(2-(4-(3-((4-(2-(2-Cyano-4,4-Difluoropyrrolidin-1-Yl)-2-Oxoethylcarbamoyl)-Quinolin-6-Yl)(Methyl)Amino)-Propyl)Piperazin-1-Yl)-2-Oxoethyl)-68Ga-[1,4,7,10]-Tetraazacyclododecane-1,4,7-Triyl)Triacetate
  • Sponsor:Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

Type 2 diabetes mellitus

Not yet recruiting

Comparison of weekly insulin icodec versus daily basal insulin in adults with type 2 diabetes who have not used insulin before

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:INSULIN DEGLUDEC
  • Sponsor:Novo Nordisk A/S

Neuronal ceroid lipofuscinosis

Not yet recruiting

First study of TTX-381 gene therapy safety in patients with eye problems caused by CLN2 disease (Neuronal Ceroid Lipofuscinosis Type 2)

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:TTX-381
  • Sponsor:Tern Therapeutics LLC

Urea cycle disorder

Not yet recruiting

Study of CMP-CPS-001 injection in healthy volunteers and patients with abnormal ornithine transcarbamylase (OTC) genotype for treating urea cycle disorders

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:0–17 years · 18–64 years · Healthy volunteers
  • Substances:AMMONIUM (15N) CHLORIDE
  • Sponsor:Camp4 Therapeutics Corp.

Type 2 diabetes mellitus

Not yet recruiting

Study of semaglutide effects on inflammation markers in patients with type 2 diabetes mellitus who have high cardiovascular risk

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Semaglutide
  • Sponsor:Universita' Degli Studi Di Napoli Federico II

Chondrocalcinosis

Not yet recruiting

Study of tocilizumab compared to placebo in patients with chronic chondrocalcinosis who did not respond to standard treatments

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Sodium Chloride
  • Sponsor:Assistance Publique Hopitaux De Paris

Coronary artery disease+2

Not yet recruiting

Study of Rosuvastatin Effects on Coronary Artery Plaque Volume in Patients with Stable Chest Pain Using CT Imaging

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Rosuvastatin
  • Sponsor:Semmelweis University

Obesity

Not yet recruiting

Comparison of Opioid-Free versus Opioid-Based General Anesthesia for Reducing Nausea and Vomiting After Robotic Bariatric Surgery in Obese Patients (ANGELO Study)

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Dexmedetomidine
  • Sponsor:Institut De Recerca Biomedica De Lleida Fundacio Dr. Pifarre

Anorexia nervosa

Not yet recruiting

Study on the Effects of Psilocybin for Young Adults with Anorexia Nervosa

InvestigationalNo placebo
Countries:SwedenSweden
  • Participants:0–17 years · 18–64 years
  • Substances:Dry Extract From Psilocybe Cubensis (15-25:1), Extraction Solvent: Methanol
  • Sponsor:Region Skane

Hypercalciuria

Not yet recruiting

Study on Vitamin D Supplementation (Colecalciferol) and Its Effect on Urinary Calcium Levels in Children and Teens Aged 2 to 18 Years

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · Healthy volunteers
  • Substances:Colecalciferol
  • Sponsor:Centre Hospitalier Universitaire De Montpellier

Gestational diabetes

Not yet recruiting

Study on Imaging Beta Cells in Patients with a History of Gestational Diabetes Using Exenatide

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · Healthy volunteers
  • Substances:Exenatide
  • Sponsor:Stichting Radboud University Medical Center

Glycogen storage disease type II

Not yet recruiting

Study on the Effects of Alglucosidase Alfa Enzyme Therapy in Children and Adults with Pompe Disease

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:0–17 years · 18–64 years · 65+ years · Healthy volunteers
  • Substances:Alglucosidase Alfa
  • Sponsor:Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

Substances studied in this area

The therapies tested most often in Metabolism and nutrition disorders trials.

Semaglutide76 clinical trialsSodium Chloride25 clinical trialsDapagliflozin23 clinical trialsEmpagliflozin16 clinical trialsCagrilintide15 clinical trialsPlacebo15 clinical trialsColecalciferol14 clinical trialsTirzepatide13 clinical trialsParacetamol12 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.